Keywords: GlaxoSmithKline, Theravance, Umeclidinium, Vilanterol, COPD, UMED/VI

Positive new Ph III data from GlaxoSmithKline and Theravance on UMEC/VI

Article | 02 July 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) this morning announced the results of four pivotal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in